Granted Patent B2

US 8,858,937 · App. 13/773,473 · Granted Oct 14, 2014

Inventors: Gregory Alan Lazar (Indianapolis, IN); Arthur J. Chirino (Camarillo, CA); Wei Dang (Pasadena, CA); John Desjarlais (Pasadena, CA); Stephen K. Doberstein (San Francisco, CA); Robert J. Hayes (Radnor, PA); Sher Bahadur Karki (Santa Monica, CA); Omid Vafa (Monrovia, CA)

Assignee: Xencor, Inc.

C07K16/4291C07K16/2887C07K16/2893A61K39/3955C07K16/00C07K16/22C07K2317/52C07K16/2863C07K2317/34C07K2317/732A61K39/395C07K16/32C07K2317/72C07K2317/734A61K39/39566C07K16/2896C07K16/2875C07K2317/77A61K2039/505

Abstract

Claims (9)

1. A method of mediating antibody-dependent cell-mediated cytotoxicity (ADCC) in a human comprising administering to a human a composition comprising a variant antibody of a parent antibody which variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of human peripheral blood mononuclear cells more effectively than the parent antibody, wherein said variant comprises a 332E substitution in the Fc region, wherein numbering is according to the EU index.

2. A method of mediating antibody-dependent cell-mediated cytotoxicity (ADCC) in a human comprising administering to a human a composition comprising a variant antibody of a parent antibody which variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of human peripheral blood mononuclear cells more effectively than the parent antibody, wherein said variant comprises a 332D substitution in the Fc region, wherein numbering is according to the EU index.

3. A method according to claim 1 or 2 wherein said variant antibody is a monoclonal antibody.

4. A method according to claim 1 or 2 wherein said variant antibody is a humanized antibody.

5. A method according to claim 1 or 2 wherein said variant antibody is a chimeric antibody.

6. A method according to claim 1 or 2 wherein said antibody binds to CD19.

7. A method according to claim 1 or 2 wherein said antibody binds to IgE.

8. A method according to claim 1 or 2 wherein said parent antibody is a human IgG1.

9. A method according to claim 1 or 2 wherein said variant antibody binds to a target antigen selected from the group consisting of CD20, CD30, CD33, CD37, CD38 and CD3.

Assignments (1)

Continuity (8)